title: Ductal carcinoma in situ - update on risk assessment and management.
abstract: Ductal carcinoma in situ (DCIS) accounts for ~20-25% of breast cancers. While DCIS is not life-threatening, it may progress to invasive carcinoma over time, and treatment intended to prevent invasive progression may itself cause significant morbidity. Accurate risk assessment is therefore necessary to avoid over- or undertreatment of an individual patient. In this review we will outline the evidence for current management of DCIS, discuss approaches to DCIS risk assessment and challenges facing identification of novel DCIS biomarkers.
authors.affiliation: Department of Pathology, Peter MacCallum Cancer Centre, East Melbourne, Vic., Australia.|Department of Pathology, University of Melbourne, Melbourne, Vic., Australia.
authors.forename: Jia-Min B
authors.initials: JM
authors.lastname: Pang
authors.affiliation: Department of Pathology, University of Melbourne, Melbourne, Vic., Australia.|Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Vic., Australia.|Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Vic., Australia.
authors.forename: Kylie L
authors.initials: KL
authors.lastname: Gorringe
authors.affiliation: Department of Pathology, Peter MacCallum Cancer Centre, East Melbourne, Vic., Australia.|Department of Pathology, University of Melbourne, Melbourne, Vic., Australia.|Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Vic., Australia.
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Fox
mesh_terms: D001943:Breast Neoplasms / Q000473:pathology*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000473:pathology*; D019468:Disease Management; D018450:Disease Progression; D005260:Female; D006801:Humans; D018570:Risk Assessment
keywords: breast neoplasms; clinical markers; clinical pathology; patient care management